Led · Series B · Jan 2024

On February 24, 2021, 依生生物制药有限公司 announced completion of a Series B financing of more than $130 million. The round was co‑led by Oceanpine Capital (海松资本) and OrbiMed (奥博资本). Following the transaction, the company's institutional investor base included Oceanpine, OrbiMed, 斯道资本, F‑Prime Capital, 3W Capital, 高瓴资本, Adjuvant Capital, 和玉资本, AIHC, 益普资本, Superstring Capital and 海通国际. 易凯资本 served as the company's exclusive financial adviser on the deal. The financing expanded the company's investor roster and represents a significant recapitalization event at the B‑round stage. No additional product, operational or use‑of‑proceeds details for the company were provided in the articles.

Participated · Series B · Aug 2021

SVOLT is an EV battery manufacturer led by Chairman and CEO Yang Hongxin that develops battery systems including cobalt-free chemistries. The company operates seven R&D centers in Japan, South Korea, the US, India, Wuxi, Baoding and Shanghai and has applied for more than 2,400 patents, including ~800 invention patents and 50 PCT international patents. SVOLT has secured 25 sales points with domestic and international mainstream automakers and more than 10 models powered by its battery system have been announced, including the ORA Cherry Cat using its cobalt-free battery. The company won a large purchase order of 16 billion yuan from Stellantis and is entering high-end markets in Europe and the US. SVOLT plans rapid capacity expansion with new bases in Changzhou, Suining, Huzhou, Ma’anshan, Nanjing and Europe and expects production capacity to exceed 200 GWh in 2025. The Series B proceeds will be used mainly for R&D of new technologies and construction of new factories.

Participated · Series B · Apr 2021

Hepagene Therapeutics Inc. is a clinical-stage drug discovery and development firm focused on therapies for liver diseases. Since its inception in 2016 the company has focused on indications including non-alcoholic steatohepatitis, chronic hepatitis B infection and cancer. The company said it will use the proceeds to support the clinical research of its pipeline candidates. It recently completed a $40 million Series B1 round. Investors in that round include Loyal Valley Capital, Oceanpine Capital and existing investor Apricot Capital. Loyal Valley Capital is described in the announcement as a ByteDance backer.

Led · Series B · Mar 2021

Immune-Onc Therapeutics is a private, clinical-stage cancer immunotherapy company developing novel myeloid checkpoint inhibitors targeting the LILRB family. Its lead clinical candidates are IO-108, an antagonist antibody targeting LILRB2 (ILT4) in Phase 1 for advanced solid tumors, and IO-202, a first-in-class antagonist antibody targeting LILRB4 (ILT3) in Phase 1 for AML, CMML and solid tumors. Additional pipeline assets include IO-106 (a LAIR1 antagonist), IO-312 (a bispecific targeting LILRB4) and multiple undisclosed programs. The company has collaborations and supply agreements with Regeneron and BeiGene to evaluate IO-108 and IO-202 in combination with anti-PD-1 therapies, and has received research grants from the NCI and CIRM. Headquartered in Palo Alto, California, Immune-Onc has also received strategic investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program (LLS TAP) and Wuxi Biologics HealthCare Venture. Management highlighted ongoing clinical milestones including dose escalation and expansion cohorts, FDA Fast Track designation for IO-202 in relapsed or refractory AML, and plans to further characterize biomarkers and mechanisms of action. Immune-Onc Therapeutics is a clinical-stage cancer immunotherapy company focused on developing novel biotherapeutics that target immunosuppressive myeloid checkpoints, specifically the LILRB family. Its lead program, IO-202, is a first-in-class antibody against LILRB4 (ILT3) being developed for acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors; preclinical data indicate it can activate T-cell killing and enhance tumor cell detection. IO-202 entered a Phase I trial in September 2020 for AML with monocytic differentiation and CMML and received FDA Orphan Drug Designation for AML in October 2020. The company’s IO-108, an antagonist antibody targeting LILRB2 (ILT4), is in the IND‑enabling stage with plans to submit an IND in mid‑2021; other preclinical assets include IO-106 (anti-LAIR1) and multiple undisclosed programs. Immune-Onc has invested in proprietary models, assays and tools to interrogate myeloid biology and maintains strategic research collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Financially, the company has raised over $110 million since beginning operations in 2016 and is advancing its pipeline toward additional clinical milestones using newly raised capital. Immune-Onc Therapeutics is focused on the discovery and development of novel biologic treatments that target the tumor microenvironment and immune suppressive pathways. The company aims to translate unique scientific insights into first-in-class biotherapeutics and has a pipeline built on collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Headquartered in Palo Alto, California, Immune-Onc is preparing to move from translational research into the clinic. To support that transition it received Series B funding of more than $33 million to advance its pipeline programs. The company recently appointed Dr. Adrian Jubb as Chief Medical Officer and Dr. An Song as Senior Vice President of Development Sciences to lead clinical, regulatory, and translational development efforts. Immune-Onc describes a leadership team with deep drug-development experience drawn from leading biotechnology and pharmaceutical organizations. Immune-Onc Therapeutics is a Palo Alto, CA-based biopharmaceutical company co-founded in 2016 by Charlene Liao, Ph.D., and Guo-Liang Yu, Ph.D. The company focuses on discovering and developing novel therapeutic antibodies for cancer treatment. It applies scientific insights and drug-development expertise to advance immuno-oncology products. Immune-Onc plans to use its new financing to support discovery and development activities for its antibody programs. In June 2016 it raised $7M in a Series A to provide initial funding to advance its pipeline.

Led · Series B · Mar 2021

YishengBio discovers, develops and commercializes biotherapeutics and vaccines using its PIKA® immunomodulating technology platform. Its commercial product, the YSJA™ alum-free lyophilized rabies vaccine, has been launched in China and provided post-exposure protection to over 16 million patients. The company reports more than 60 patents on PIKA technology across over 30 countries and regions. Its clinical pipeline includes candidates such as YS-ON-001 for advanced solid tumors, YS-HBV-001 for hepatitis B, and PIKA YS-SC2-010 for COVID-19, with other candidates in preclinical and discovery stages. YishengBio operates in China, the USA and Singapore and has over 500 employees. The company plans to expand R&D capacity, accelerate commercialization and advance multiple clinical programs, supported by recent financing to build biologics production facilities in China and Singapore.